首页> 中文期刊> 《中国肿瘤临床》 >肺癌诊治和预后判断分子标志物miRNA

肺癌诊治和预后判断分子标志物miRNA

         

摘要

肺癌是目前全世界发病率第一、死亡率最高的肿瘤。肺癌的早期诊断和有效治疗是提高患者生存率的关键。miR-NA是一类内源性、高度保守的非编码小分子RNA,在肺癌的发生、发展中起着重要作用。近年来,肺癌诊断、治疗和预后判断分子标志物miRNA的研究进展迅速,本文就miRNA作为肺癌早期诊断、预后判断和疗效预测分子标志物的研究进展,以及目前存在的问题做一综述。%Lung cancer has the highest morbidity and mortality rate among malignant tumors. Early diagnosis and effective treat-ment are the keys to improving the survival of lung cancer patients. A type of endogenous, highly conserved, non-coding small mole-cule RNA (i.e., miRNA) was found to play an important role in the occurrence and development of this disease. Research on this molec-ular marker miRNA for the diagnosis, treatment and prognosis of lung cancer has rapidly progressed. This paper reviews the research work on miRNA as a molecular marker in the early diagnosis, treatment efficacy, and prognosis of lung cancer and explores some ques-tions related to this disease.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号